12 compounds against SARS-CoV-2 in Calu-3 cells from Biering et al.	The authors used a library of FDA-approved and well-studied preclinical and clinical compounds to screen for antivirals against SARS-CoV-2 in human pulmonary epithelial (Calu-3) cells. Drugs are from Figure 3 of Biering et al. (2020) Screening a library of FDA-approved and bioactive compounds for antiviral activity against SARS-CoV-2. bioRxiv, 12/30/2020.	remdesivir	budesonide	cyclosporin a	dinaciclib	cantharidin	sc66	gc376 sodium	camostat mesylate	b02	gkt137831	bfh772	azd5438
12 hits from an in-vitro drug screen for approved drugs as COVID-19 inhibitors from Touret et al.	In-vitro drug screen for approved drugs as COVID-19 inhibitors	remdesivir	hydroxychloroquine	dolutegravir	omeprazole	alprostadil	clemizole hydrochloride	quinidine hydrochloride	oxprenolol hydrochloride	azithromycine	opipramol dihydrochloride	arbidol	sulfadoxine
14 drugs inhibiting SARS-CoV-2 Mpro in vitro from Ghahremanpour et al.	Virtual screening of 2,000 drugs for inhibition of SARS-CoV-2 MPro was performed, and 17 were tested in vitro. 14 of these drugs were found effective at low concentrations. Drugs sourced from Figure 2 of Ghahremanpour et al. Identification of 14 Known Drugs as Inhibitors of the Main Protease of SARS-CoV-2. bioRxiv, v1 preprint, 8/28/2020.	nelfinavir	indinavir	lapatinib	bedaquiline	boceprevir	idarubicin	azelastine	perampanel	talampicillin	periciazine	lercanidipine	efonidipine	manidipine	cinnoxicam
15 SARS-CoV-2 inhibitors in Vero E6 cells from Jan et al. 2021	Jan et al. screened in Vero E6 cells 3,000+ agents used in humans and animals, including 2,855 small molecules and 190 traditional herbal medicines, and identified 15 active small molecules in concentrations ranging from 0.1 nM to 50 μM. Drugs are from Table 1 & Figure 1.	mefloquine	cepharanthine	nelfinavir	ivacaftor	penfluridol	salinomycin	ivermectin	emetine	thioguanine	boceprevir	dronedarone	monensin	moxidectin	maduramicin	azelnidipine
16 validated hits from 20 prioritized compounds by Weston et al.	Took top hits from a MERS screen from 2014 and validated these for COVID-19. 17 out of 20 worked for COVID-19 in Vero cells.	hydroxychloroquine	mefloquine	chloroquine	chlorpromazine	fluspirilene	triparanol	toremifene	tamoxifen	promethazine	imatinib	thiethylperazine	clomipramine	amodiaquin	benztropine	terconazole	fluphenazine
25 compounds against SARS-CoV-2 via AlphaLISA RBD-ACE2 assay from Hanson et al.	The AlphaLISA RBD−ACE2 platform was developed to assess binding of SARS-CoV-2 spike protein receptor binding domain (RBD) to ACE2. Using this platform, 3,384 small-molecule drugs and preclinical compounds were screened. 25 high-quality primary hits resulted, of which only corilagin was validated. 25 hits from Supplementary Table S2 in Hanson et al. (2020) Targeting ACE2−RBD Interaction as a Platform for COVID-19 Therapeutics: Development and Drug-Repurposing Screen of an AlphaLISA Proximity Assay. ACS Pharmacology & Translational Science, 3(6): 1352-1360.	entacapone	cisplatin	cetylpyridinium chloride	bictegravir	mebendazole	prulifloxacin	fenbendazole	oxfendazole	hinokitiol	corilagin	nh125	cangrelor (ar-c69931)	triethylenetetramine	toltrazuril	agaric acid	cabotegravir (gsk744, gsk1265744)	picolinic acid	enalapril maleate	elaidic acid	abametapir	gsk1349572	sodium deoxycholate monohydrate	ciclopirox	9(z)-hexadecenoic acid	benzylhexadecyldimethylammonium chloride
27 hits from an in-vitro COVID-19 drug screen from Jeon et al.	In-vitro drug screen for COVID-19 repurposing	lopinavir	amodiaquine	remdesivir	mefloquine	chloroquine	cepharanthine	bazedoxifene	anidulafungin	eltrombopag	cyclosporine	loperamide	proscillaridin	niclosamide	digoxin	ivacaftor	digitoxin	abemaciclib	tilorone	hydroxyprogesterone	ciclesonide	berbamine	tetrandrine	oxyclozanide	ouabain	salinomycin	gilteritinib	hexachlorophene
29 FDA-approved drugs inhibiting SARS-CoV-2 in Vero cells from Ku et al. (2020)	In this study, 1,473 FDA-approved drugs as well as remdesivir (used as a positive control) were screened using cell-based assays to identify inhibitors of SARS-CoV-2 infection. The antiviral activity of each compound was measured based on the immunofluorescent staining of infected cells using anti-dsRNA antibody. Twenty-nine drugs were found to show antiviral activity against SARS-CoV-2. Drugs taken from Tables 1 & 2. Ku et al. (2020) Repurposing screens of FDA-approved drugs identify 29 inhibitors of SARS-CoV-2. J Microbiol Biotechnol (11/10/2020).	amodiaquine	eltrombopag	loperamide	losartan	salinomycin	promethazine	imatinib	celecoxib	masitinib	flunarizine	reserpine	bromhexine	asenapine	thioproperazine	micafungin	selexipag	tiratricol	beclamide	hydroquinidine	quinidine	nkh 477	lomerizine	diphenylpyraline	vinpocetine	dibucaine	vemurafenib (plx4032)	buclizine	ethopropazine	meclizine
69 hits from an in-vitro COVID-19 drug screen from Ellinger et al.	In-vitro drug screen for COVID-19 repurposing	lopinavir	remdesivir	mefloquine	loratadine	almitrine	camostat	pevonedistat	octenidine	nafamostat	papaverine	apixaban	alvocidib	methylene blue	emetine	cycloheximide	amuvatinib	thimerosal	homoharringtonine	hematoporphyrin	posaconazole	polidocanol	drotaverine	ketoconazole	alisporivir	regorafenib	loteprednol etabonate	lidoflazine	chlormidazole	tyrphostin	avasimibe	brexpiprazole	sorafenib	lonafarnib	ethaverine	dapivirine	flunarizine	jte-013	nsc319726	ravuconazole	mibampator	ly2228820	cloconazole	oxiconazole	zk-93423	ipag	ai-10-49	gsk2606414	lde225	cetylpyridinium chloride	avatrombopag	thioguanosine	ph-797804	adoprazine	sb-612111	etifoxine	harringtonine	dcpib	pf-670462	cc-223	vatalanib	tioguanine	bp-897	amg-9810	pexidartinib	lgk-974	ac1ndss5	vlx600	carboxyamidotriazole	cbipes
All 30 drugs from a screen for COVID-19 by Riva et al. 	In-vitro drug screen for COVID-19 drugs in Vero cells. Screened 12,000 candidates. 	remdesivir	tetrandrine	tretinoin	apilimod	clofazimine	tamibarotene	rbad	al 3152	aq-13	tazarotene	astemizole	zk-93426	zaleplon gr	pagoclone	acitretin	lgd-1550	sdz-62-434	ono 5334	n-tert-butylisoquine	amg-2674	kw 8232	yh-1238	z lvg chn2	elopiprazole	mdl-28170	vby-825	sl-11128	sb-616234-a	mln-3897	8-(3-Chlorostyryl)caffeine
Drug Repurposing Screen for Compounds Inhibiting the Cytopathic Effect of SARS-CoV-2 from Chen et al.	55 compounds from Drug Repurposing Screen for Compounds Inhibiting the Cytopathic Effect of SARS-CoV-2	amodiaquine	remdesivir	loperamide	imatinib	stf-62247	apilimod	fluoxetine	vby-825	flunarizine	clemastine	duloxetine	berzosertib	z-fa-fmk	chlorprothixene	z-gly-leu-phe-chloromethyl ketone	sb-271046	ml-414	dexanabinol	idalopirdine	ly 426965	alpha-l-arabinopyranose	gmc 2-29	deserpedine	n-methylspiperone	maprotiline	trifluomeprazine	s-15176	balicatib	cpdd	difeterol	am1241	amodiarone	caa-0225	jtv519	asteriscunolide d	mcoppb	naltrindole	melitracen	gmc 2-113	genz-123346	calpeptin	methotrimeprazine	piperacetazine	dmp-777	ikk-2 inhibitor viii	it1t	gw-803430	cathepsin inhibitor 1	vps-34-in1	nsc-33994	rescimetol	calpain inhibitor i	proglumetacin	pristimerin	methdilazine
Drug repurposing screens reveal FDA approved drugs active against SARS-Cov-2 from Dittmar et al.	Drug repurposing screens reveal FDA approved drugs active against SARS-Cov-2	cepharanthine	cyclosporine	ebastine	tetrandrine	salinomycin	aloxistatin	dacomitinib	bemcentinib	z-fa-fmk	wye-125132	azd-8055	pf-04691502	bix-01294	unc0631	dp44mt	leupeptin hemisulfate	naquotinib	mg-101	pd0166285	y-320	am-1241	frax486	mg-132
Identification of potent and safe antiviral therapeutic candidates against SARS-CoV-2	Drug screen for FDA approved drugs to block SARS-CoV-2 in-vitro	hydroxychloroquine	mefloquine	digoxin	tilorone	amlodipine	trifluoperazine	tetrandrine	ouabain	lanatoside c	raloxifene	sertraline	nilotinib	celecoxib	arbidol	clofazimine	temsirolimus	conivaptan	vortioxetine	thioridazine	dronedarone	fendiline	salifungin	monensin	actidione
Massive-scale biological activity-based modeling identifies novel antiviral leads against SARS-CoV-2	Massive-scale biological activity-based modeling identifies novel antiviral leads against SARS-CoV-2	triparanol	importazole	skf-525a	bd-1008	methoxytropane hydrochloride	chlorprothixene	bucindolol	hexahydro-sila-difenidol hydrochloride	l-741626	amn-082	rimcazole	spiramide	thioproperazine	prenylamine	cgs-12066b	zolantidine	lp 44	oxycarboxin	amindocate	ftormetazine	metaphit	alimemazine	oxalate	pecazine	bemesetron	eticlopride	prestwick-559	gbr-12935	ucl-2077	octoclothepine	oryzalin	bepp	4-aminoazobenzene	indocate
Morphological Cell Profiling of SARS-CoV-2 Infection Identifies Drug Repurposing Candidates for COVID-19 from Mirabelli et al.	Morphological Cell Profiling of SARS-CoV-2 Infection Identifies Drug Repurposing Candidates for COVID-19	remdesivir	niclosamide	gilteritinib	fedratinib	amiodarone	verapamil	entecavir	clofazimine	tioguanine	bosutinib	z-fa-fmk	metoclopramide	s1ra	lomitapide	lactoferrin
Top 39 drugs from an image-based screen for COVID-19 by Heiser et al. 	Image-based analysis of renal cortical epithelial cells infected with COVID-19 and treated with 1670 drugs	remdesivir	almitrine	paricalcitol	vincristine	ponatinib	rapamycin	hexachlorophene	carvedilol	nitazoxanide	nilotinib	pacritinib	everolimus	clofazimine	levobetaxolol	doxercalciferol	nebivolol hcl	calcipotriene	vismodegib	temsirolimus	aloxistatin	dexpropranolol	zotarolimus	trihexyphenidyl	cloperastine	celiprolol	int-747	bupranolol	cloranolol	ipi-145	cx-4945	penbutolol	byl719	carazolol	gs-441524	triclocarban	hydroxystilbamidine	acitretin	calcifediol	oxybenzone